Roche moved to expand oncology diagnostics into an end-to-end platform strategy by pursuing acquisitions in digital pathology and MRD monitoring. At its diagnostics day, the company described pending deals including a $1.05 billion acquisition of PathAI and a $595 million acquisition of Saga Diagnostics, while preparing a new sequencing instrument launch later this year. Roche executives positioned PathAI as complementary to Ventana tissue pathology and its pharma services operations, pointing to potential earlier engagement with pharmaceutical partners on companion diagnostic programs. Roche also emphasized Pathlight MRD from Foundation Medicine’s acquisition of Saga as a tool for earlier detection of recurrence. The company’s instrument, Axelios, was described as a driver for growth in molecular-based oncology testing and already used in early access at Foundation Medicine and select sites in the U.S. and Europe. For biotech developers, the strategy can affect how companion diagnostics are built and validated across molecular and tissue testing workflows. The key watch item is whether Roche can integrate PathAI’s tools with existing pathology and sequencing capabilities fast enough to convert into measurable partner adoption and clinical evidence generation.